Reilly Financial Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Reilly Financial Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,500	Closed	-$50K	–	969
2019 Q2	$50K	Hold	1,500	–	–	0.01%	364
2019 Q1	$53K	Hold	1,500	–	–	0.01%	344
2018 Q4	$50K	Hold	1,500	–	–	0.01%	330
2018 Q3	$76K	Hold	1,500	–	–	0.01%	290
2018 Q2	$90K	Hold	1,500	–	–	0.01%	231
2018 Q1	$69K	Hold	1,500	–	–	0.01%	264
2017 Q4	$60K	Sell	1,500 -500	-25%	-$19.8K	0.01%	301
2017 Q3	$80K	Hold	2,000	–	–	0.01%	248
2017 Q2	$86K	Hold	2,000	–	–	0.01%	234
2017 Q1	$63K	Hold	2,000	–	–	0.01%	263
2016 Q4	$51K	Hold	2,000	–	–	0.01%	275
2016 Q3	$49K	Hold	2,000	–	–	0.01%	270
2016 Q2	$41K	Buy	+2,000	New	+$35.5K	0.01%	277

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

ACM

Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

Reilly Financial Advisors's SUPN Position: Q3 2019 in Review

Reilly Financial Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q3 2019, closing a stake of 1,500 shares — an estimated $50K sold.

Reilly Financial Advisors first reported a position in SUPN in Q2 2016 and held it in 13 quarters. The position peaked at $90K in Q2 2018. 243 funds tracked by Wall St. Rank hold SUPN as of Q3 2019.

Reilly Financial Advisors reported no remaining Supernus Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Reilly Financial Advisors sold 1,500 Supernus Pharmaceuticals shares in Q3 2019, an estimated $50K.
Reilly Financial Advisors first reported a position in Supernus Pharmaceuticals in Q2 2016 and held it in 13 quarters.
Reilly Financial Advisors's Supernus Pharmaceuticals position peaked at $90K in Q2 2018.
243 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2019.

Based on Reilly Financial Advisors's 13F filing for Q3 2019, filed 15 Oct 2019.